Rare Benign Fibrous Bone Tumour
- BENIGN FIBROUS HISTIOCYTOMA OF BONE (BFHB) is a RARE benign mesenchymal tumour - according to PubMed representing less than 1% of all benign bone tumours - and is a somewhat CONTROVERSIAL entity, histologically characterised by a mixture of FIBROBLASTS arranged in a STORIFORM (cartwheel) pattern with varying amounts of OSTEOCLAST-TYPE GIANT CELLS and FOAMY (lipid-laden) MACROPHAGES.
- Its histology is essentially IDENTICAL to that of the common NON-OSSIFYING FIBROMA (NOF)/fibrous cortical defect, so BFHB is distinguished from NOF on CLINICAL and radiological grounds rather than histology alone: it tends to occur in ATYPICAL LOCATIONS (pelvis, axial skeleton, and the diaphysis or epiphysis of long bones) and in OLDER patients who are usually SYMPTOMATIC (painful), in contrast to the typical young, asymptomatic, metaphyseal NOF that regresses.
- It is a BENIGN tumour, and CURETTAGE or simple RESECTION is usually CURATIVE; however, it has a meaningful LOCAL RECURRENCE rate - up to about 11% of patients relapse - so follow-up is warranted, and there are RARE reports of MALIGNANT TRANSFORMATION (to a high-grade sarcoma).
- DIAGNOSIS is largely one of EXCLUSION: because the histology overlaps with other lesions, the differential (giant cell tumour of bone, non-ossifying fibroma, fibrous dysplasia, aneurysmal bone cyst, chondromyxoid fibroma) must be excluded by correlating the clinical picture, imaging (a well-defined lytic lesion, often with a sclerotic rim) and histology, ideally at a specialist bone-tumour centre.
- It is worth noting that the historical term 'malignant fibrous histiocytoma' is a SEPARATE, MALIGNANT entity now largely reclassified as UNDIFFERENTIATED PLEOMORPHIC SARCOMA - it must NOT be confused with benign fibrous histiocytoma of bone, which is benign.
- MANAGEMENT is therefore: confirm the diagnosis (excluding mimics) on imaging and biopsy, treat by CURETTAGE (with grafting) or simple resection, with bone grafting/fixation as needed for structural lesions, and FOLLOW UP for recurrence; the rare aggressive/recurrent or transformed lesion is managed more aggressively at a sarcoma unit.
- “Benign fibrous histiocytoma of bone (BFHB) = rare (<1% of benign bone tumours), histologically IDENTICAL to non-ossifying fibroma (storiform fibroblasts + osteoclast-type giant cells + foamy macrophages).
- “Distinguished from NOF CLINICALLY: ATYPICAL site (pelvis/axial/diaphysis-epiphysis) + OLDER, SYMPTOMATIC patients (vs young, asymptomatic, metaphyseal NOF).
- “Benign; curettage/resection usually curative but up to ~11% RECUR (follow up); RARE malignant transformation. Diagnosis of exclusion. Do NOT confuse with 'malignant fibrous histiocytoma' (= undifferentiated pleomorphic sarcoma, malignant).
Histology like a non-ossifying fibroma (storiform fibroblasts + giant cells + foamy macrophages) but in an atypical site (pelvis/axial/diaphysis-epiphysis) and an older, symptomatic patient = BFH of bone.
Malignant fibrous histiocytoma is a different, malignant tumour (now undifferentiated pleomorphic sarcoma). BFH of bone is benign (but up to ~11% recur; rare transformation).
What It Is & How It Differs from NOF
Benign fibrous histiocytoma of bone is a rare benign fibrous tumour (less than 1% of benign bone tumours), histologically a storiform proliferation of fibroblasts with osteoclast-type giant cells and foamy macrophages - identical to non-ossifying fibroma. It is separated from NOF clinically: it occurs in atypical locations (pelvis, axial skeleton, long-bone diaphysis/epiphysis) and in older, symptomatic patients, whereas NOF is typically young, asymptomatic and metaphyseal. It is benign but recurs in a notable minority (up to ~11%) after curettage, with rare malignant transformation, and the diagnosis is largely one of exclusion of other giant-cell-rich/fibrous lesions.
| Feature | Benign fibrous histiocytoma of bone | Non-ossifying fibroma |
|---|---|---|
| Histology | Storiform fibroblasts + giant cells + foamy macrophages | Identical |
| Age | Older (adults) | Children/adolescents |
| Site | Atypical (pelvis/axial/diaphysis-epiphysis) | Metaphysis of long bones (eccentric, cortical) |
| Symptoms | Usually symptomatic (painful) | Usually asymptomatic/incidental |
| Course | Benign; up to ~11% recur; rare transformation | Benign; regresses/heals spontaneously |
Management
- Diagnosis: correlate clinical picture, imaging (well-defined lytic lesion +/- sclerotic rim) and histology; exclude giant cell tumour, NOF, fibrous dysplasia, aneurysmal bone cyst, chondromyxoid fibroma - ideally at a specialist bone-tumour centre.
- Treatment: curettage (with bone grafting) or simple resection, with grafting/fixation for structural lesions - usually curative.
- Follow up: for local recurrence (up to ~11%).
- Aggressive/recurrent/transformed lesions: managed more aggressively at a sarcoma unit (rare malignant transformation).
Two cautions matter with benign fibrous histiocytoma of bone. First, because its histology is identical to the common non-ossifying fibroma and overlaps with several giant-cell-rich lesions, the diagnosis is essentially one of exclusion: the clinical setting (older, symptomatic patient; atypical location), the imaging and the histology must be correlated, ideally at a specialist bone-tumour centre, so that more significant lesions - particularly giant cell tumour of bone - are not missed. Second, the nomenclature is a trap: 'malignant fibrous histiocytoma' is a wholly different, malignant tumour, now largely reclassified as undifferentiated pleomorphic sarcoma, and must not be conflated with the benign entity. While BFH of bone is benign and usually cured by curettage or simple resection, it recurs in a notable minority and has rare reports of malignant transformation, so follow-up is appropriate and any aggressive, recurrent or transformed lesion should be referred for specialist management.
Evidence & Key Studies
Recurrent benign fibrous histiocytoma of bone with later malignant transformation
- Benign fibrous histiocytoma of bone is a rare mesenchymal tumour, representing less than 1% of all benign bone tumours, characterised by a mixture of fibroblasts in a storiform pattern with varying amounts of osteoclast-type giant cells and foamy macrophages.
- Curettage or simple resection is usually curative, but up to 11% of patients suffer relapse.
- The report documents malignant transformation of a benign fibrous histiocytoma of bone (a rare event), reinforcing the need for follow-up.
According to PubMed, the rarity (less than 1% of benign bone tumours), the storiform fibroblastic histology with osteoclast-type giant cells and foamy macrophages, the usual cure by curettage/simple resection with up to about 11% relapse, and the rare malignant transformation come from the cited Wetterwald report. The histological identity with non-ossifying fibroma and the clinical distinction (atypical site, older/symptomatic patients), the status as a diagnosis of exclusion, and the separation from 'malignant fibrous histiocytoma' (undifferentiated pleomorphic sarcoma) are standard, well-established teaching. (See also our Non-Ossifying Fibroma, Giant Cell Tumour of Bone and Fibrous Dysplasia topics.)
Clinical Decision Scenarios
Practise clinical reasoning and management decisions out loud
“A biopsy of a painful pelvic lytic lesion in an adult shows storiform fibroblasts with giant cells and foamy macrophages. What is the diagnosis and how do you manage it?”
Mnemonics & Memory Aids
STORIFORM
Hook:STORIFORM: Storiform/giant cells/foamy macrophages, aTypical site+older, exclude Other lesions, Infrequent, curette/resect, recur ~11%, not Malignant FH.
What it is
- Rare benign fibrous bone tumour (<1% of benign bone tumours)
- Histology = storiform fibroblasts + osteoclast-type giant cells + foamy macrophages (like NOF)
- Controversial entity
Distinguished from NOF
- Atypical site: pelvis, axial skeleton, long-bone diaphysis/epiphysis
- Older, usually symptomatic (painful) patients
- NOF = young, asymptomatic, metaphyseal, regresses
Behaviour & management
- Benign; curettage (+graft) or simple resection usually curative
- Up to ~11% recur - follow up; rare malignant transformation
- Diagnosis of exclusion; don't confuse with malignant fibrous histiocytoma (UPS)